3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer -: A nested case-control study
3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer -: A nested case-control study
复制标题
DOI：
10.1001/archinte.160.15.2363
复制
发表时间：
2000-08-14
影响因子：
--
通讯作者：
LeLorier, J
中科院分区：
文献类型：
--
作者：
Blais, L;Desgagné, A;LeLorier, J
背景：在过去的15年里，降脂药物的处方数量呈指数级增长。这些药物对癌症的长期影响仍然存在不确定性，尤其令人担忧的是，这些治疗的持续时间可能长达几十年。目的：探讨3-羟基-3-甲基戊二酰辅酶A(HMG-CoA)还原酶抑制剂与癌症发病率的关系。方法：使用L保证-疾病登记管理健康数据库。我们在魁北克进行了嵌套式病例对照研究。我们选择了一组6721名魁北克医疗保健计划的受益者，他们在队列进入时至少一年没有癌症，年龄在65岁及以上，并接受了调脂药物治疗。队列成员是在1988至1994年间选定的，并进行了中位数2.7年的跟踪调查。从队列中，确定了542例第一恶性肿瘤患者，并随机选择了5420名对照。使用HMG-CoA还原酶抑制剂的患者与使用胆汁酸结合树脂的患者的癌症风险进行了比较。结果：使用HMG-CoA还原酶抑制剂的患者被诊断为癌症的可能性比使用胆汁酸结合树脂的患者低28%(比率比为0.72；95%可信区间为0.57-0.92)。研究中发现所有特定的癌症部位与HMG-CoA还原酶抑制剂的使用无关或呈负相关。结论：我们的研究结果为HMG-CoA还原酶抑制剂的安全性提供了一定程度的保证。
Background: During the past 15 years there has been an exponential increase in the number of prescriptions for lipid-lowering drugs. Uncertainties remain about the long-term impact of these medications on cancer, which is particularly bothersome given that the duration of these treatments may extend for several decades.Objective: To explore the association between 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors and cancer incidence.Methods: Using the administrative health databases of the Regie de l'Assurance-Maladie du. Quebec we performed a nested case-control study. We selected a cohort of 6721 beneficiaries of the health care plan of Quebec who were free of cancer for at least 1 year at cohort entry, 65 years and older, and treated with lipid-modifying agents. Cohort members were selected between 1988 and 1994 and were followed up for a median period of 2.7 years. From the cohort, 542 cases of first malignant neoplasm were identified, and 5420 controls were randomly selected. Users of HMG-CoA reductase inhibitors were compared with users of bile acid-binding resins as to their risk of cancer. Specific cancer sites were also considered.Results: Users of HMG-CoA reductase inhibitors were found to be 28% less likely than users of bile acid-binding resins to be diagnosed as having any cancer (rate ratio, 0.72; 95% confidence interval, 0.57-0.92). All specific cancer sites under study were found to be not or inversely associated with the use of HMG-CoA reductase inhibitors.Conclusion: The results of our study provide some degree of reassurance about the safety of HMG-CoA reductase inhibitors.